Article
Multidisciplinary Sciences
Nawal Al Kaabi, Abderrahim Oulhaj, Subhashini Ganesan, Farida Ismail Al Hosani, Omer Najim, Halah Ibrahim, Juan Acuna, Ahmed R. Alsuwaidi, Ashraf M. Kamour, Ashraf Alzaabi, Badreyya Ahmed Al Shehhi, Habiba Al Safar, Salah Eldin Hussein, Jehad Saleh Abdalla, Dalal Saeed Naser Al Mansoori, Ahmed Abdul Kareem Al Hammadi, Mohammed A. Amari, Ahmed Khamis Al Romaithi, Stefan Weber, Santosh Elavalli, Islam Eltantawy, Noura Khamis Alghaithi, Jumana Nafiz Al Azazi, Stephen Geoffrey Holt, Mohamed Mostafa, Rabih Halwani, Hanif Khalak, Wael Elamin, Rami Beiram, Walid Zaher
Summary: The BBIBP-CorV (Sinopharm) vaccine has been assessed for its effectiveness against severe COVID-19 disease using data from Abu Dhabi. The vaccine showed an effectiveness of 80% against hospitalization, 86% against critical care admission, and 84% against death. However, the effectiveness declined over time, suggesting the need for booster doses to increase protection against severe COVID-19 outcomes.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Xuesong Xu, Yi Hong, Erjing Chen, Yaping Wang, Biao Ma, Jiali Li, Wei Su, Yuxin Zhou, Mingzhou Zhang
Summary: This study discusses the inhibitory abilities of antibodies induced by primary and booster vaccines against different strains of SARS-CoV-2. The results show that homologous inactivated vaccines have the strongest inhibitory effects on the wild-type strain, but exhibit resistance against B.1.351, B.1.617.2, and B.1.1.529 mutants. Heterologous booster vaccination can significantly restore humoral immune responses and generate stronger antibody responses against various mutant strains.
Article
Infectious Diseases
ShengLi Xia, YunTao Zhang, YanXia Wang, Hui Wang, YunKai Yang, George Fu Gao, WenJie Tan, GuiZhen Wu, Miao Xu, ZhiYong Lou, WeiJin Huang, WenBo Xu, BaoYing Huang, Wei Wang, Wei Zhang, Na Li, ZhiQiang Xie, Xiujuan Zhu, Ling Ding, WangYang You, YuXiu Zhao, Jun Zhao, LiLi Huang, XueZhong Shi, YongLi Yang, GuangXue Xu, WenLing Wang, PeiPei Liu, Meng Ma, YuLing Qiao, SuHua Zhao, JingJing Chai, QinQin Li, Hui Fu, Ying Xu, XiaoTong Zheng, WanShen Guo, XiaoMing Yang
Summary: This study evaluated the safety and immunogenicity of the inactivated COVID-19 vaccine BBIBP-CorV in participants aged 3-17 years. The results showed that BBIBP-CorV was safe and well tolerated at all tested dose levels and induced robust antibody responses. Phase 3 trials are recommended in the population younger than 18 years to further assess its safety and protection efficacy against COVID-19.
LANCET INFECTIOUS DISEASES
(2022)
Article
Immunology
Chao Wang, Lin-Yi Chen, Qing-Bin Lu, Fuqiang Cui
Summary: Vaccination against COVID-19 is crucial for public health, and Sinopharm BBIBP-CorV, an inactivated vaccine, has been widely distributed worldwide. This article presents the evidence on the safety, efficacy, and effectiveness of BBIBP-CorV, as well as comments on a recent study comparing its effectiveness with other vaccines.
Article
Microbiology
Qinjin Wang, Jie Ning, Ying Chen, Bin Li, Liang Shi, Taojun He, Fang Zhang, Xingchi Chen, Aixia Zhai, Chao Wu
Summary: The BBIBP-CorV inactivated vaccine induces antibody responses to the receptor binding domain (RBD), nucleocapsid (N) protein, and non-structural protein 8 (NSP8). The antibody responses can be maintained for about 6 months after the second dose vaccination. The SARS-CoV-2 specific IgG response is independent of age and gender, and the peptide N391-408 is identified as a dominant peptide after BBIBP-CorV vaccination.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Immunology
Jira Chansaenroj, Nungruthai Suntronwong, Sitthichai Kanokudom, Suvichada Assawakosri, Ritthideach Yorsaeng, Preeyaporn Vichaiwattana, Sirapa Klinfueng, Lakana Wongsrisang, Donchida Srimuan, Thaksaporn Thatsanatorn, Thanunrat Thongmee, Chompoonut Auphimai, Pornjarim Nilyanimit, Nasamon Wanlapakorn, Natthinee Sudhinaraset, Yong Poovorawan
Summary: The study found that antibody levels declined significantly three months after the second dose of the BBIBP-CorV vaccine, but increased after the booster, effectively neutralizing the Delta variant. All booster vaccines induced total IFN-Y T-cell response.
Article
Immunology
Nahad Sedaghat, Masoud Etemadifar, Noushin Lotfi, Farnaz Sayahi, Ahmad Chitsaz, Mehri Salari, Alireza Ghasemi Movaghar
Summary: This study aimed to pilot larger studies by demonstrating the safety and comparing the immunogenicity of different types of third doses in seronegative pwMS after two doses of BBIBP-CorV inactivated vaccine. Results showed that pwMS receiving AV third doses showed significantly increased IgG concentrations, while only those not on aCD20 and fingolimod responded to inactivated third doses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Saad I. Mallah, Abdulla Alawadhi, Jaleela Jawad, Pearl Wasif, Basma Alsaffar, Ejlal Alalawi, Afaf Merza Mohamed, Alexandra E. Butler, Batool Alalawi, Donia Qayed, Sayed Ali Almahari, Ali Mubarak, Aalaa Mubarak, Sawsan Saeed, Ahmed Humaidan, Nitya Kumar, Stephen Atkin, Manaf Alqahtani
Summary: A study found that heterologous prime-boost vaccination with BNT162b2 and BBIBP-CorV vaccines can enhance the immune response to SARS-CoV-2 in individuals who have received two doses of a vaccine. This approach appears to be safe and well tolerated.
Article
Gastroenterology & Hepatology
Carlos King Ho Wong, Lung Yi Mak, Ivan Chi Ho Au, Francisco Tsz Tsun Lai, Xue Li, Eric Yuk Fai Wan, Celine Sze Ling Chui, Esther Wai Yin Chan, Wing Yiu Cheng, Franco Wing Tak Cheng, Man Fung Yuen, Ian Chi Kei Wong
Summary: This study found no evidence of an increased risk of acute liver injury (ALI) following COVID-19 vaccination. The risk of ALI was much higher after SARS-CoV-2 infection compared to vaccination. Therefore, the benefits of mass COVID-19 vaccination outweigh the potential risks.
JOURNAL OF HEPATOLOGY
(2022)
Article
Medicine, General & Internal
Linhua Pi, Jian Lin, Ying Zheng, Zhen Wang, Zhiguang Zhou
Summary: Subacute thyroiditis, an inflammatory disease, has been reported caused by vaccines in rare cases, including the inactivated SARS-CoV-2 vaccine. Patients may recover from symptoms and signs of subacute thyroiditis, but may require ongoing thyroxine replacement for hypothyroidism.
FRONTIERS IN MEDICINE
(2022)
Article
Medicine, General & Internal
Eva Rakoczi, Gusztav Magocs, Sara Kovacs, Bela Nagy Jr, Gabriella Szucs, Zoltan Szekanecz
Summary: In this prospective study, the efficacy of heterologous vaccination with BNT162b2 on individuals previously administered with two doses of BBIBP-CorV vaccine was analyzed. The results showed that the total Ig levels significantly increased after BNT162b2 boosters, suggesting that BNT162b2 can successfully enhance the effects of two-dose BBIBP-CorV vaccination.
Article
Multidisciplinary Sciences
Jihane Belayachi, Majdouline Obtel, Abdelkader Mhayi, Rachid Razine, Redouane Abouqal
Summary: This study provided national estimates of the real-world effectiveness of the Sinopharm vaccine, BBIBP-CorV (Vero Cells), against severe SARS-CoV-2 infection in Morocco. The results showed that the vaccine was highly protective, with effectiveness remaining stable during the first three months following the second dose and slightly decreasing thereafter, especially in individuals aged 60 years and above.
Article
Immunology
Javeria Aijaz, Shakir Hussain, Fouzia Naseer, Fatima Kanani, Sabiha Anis, Samreen Sarfaraz, Saima Saeed, Hina Farooq, Saba Jamal
Summary: 55% of the Pakistani population is unvaccinated. This study compared the seroconversion rate and antibody titers in vaccinated and unvaccinated COVID-19-recovered individuals. The results showed that the seroconversion rate was lower in vaccinated individuals, but higher in those who had previously tested positive for COVID-19. The antibody titers were lower in vaccinated individuals compared to those who had recovered from moderate to severe COVID-19, but prior exposure to SARS-CoV-2 increased the titers to a similar level.
Article
Immunology
Mariana Ulinici, Alen Suljic, Monica Poggianella, Rafaela Milan Bonotto, Katarina Resman Rus, Angela Paraschiv, Amedeo Marco Bonetti, Mihail Todiras, Alexandru Corlateanu, Stanislav Groppa, Emil Ceban, Miroslav Petrovec, Alessandro Marcello
Summary: The study evaluated the antibody levels and neutralizing potential of COVID-19 convalescent plasma and sera from Moldovan adults vaccinated with the Sinopharm BBIBP-CorV vaccine. The results showed that convalescent individuals had higher levels of antispike RBD IgG antibodies, while vaccinated individuals produced higher levels of neutralizing antibodies.
Article
Immunology
Guang Zeng, Liumei Xu, Shuidong Feng, Jie Tang, Xiaohui Wang, Guilian Li, Yongxia Gan, Chenli Zheng, Jin Zhao, Zhengrong Yang
Summary: This study aimed to evaluate the immunogenicity and immune persistence of inactivated SARS-CoV-2 vaccines in people living with HIV (PLWH) in real-world settings. The results showed that the vaccines induced lower antibody levels and seropositivity rates in PLWH compared to healthy controls. Additionally, PLWH had weaker immune responses overall.